WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV) announced today that it will present at the Credit Suisse 2017 Healthcare Conference. The event will be webcast live on Tuesday, November 7, 2017 at 5:55 p.m. EST / 3:55 p.m. MST. To access the live webcast, please visit Bioverativ’s Investors page at investors.bioverativ.com. An archived version of the webcast will be available following the presentation.
Bioverativ (NASDAQ: BIVV) is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @bioverativ on Twitter.
Susan Altschuller, Ph.D., +1 781-663-4360